Author: Moody, M. Anthony
Title: Modulation of HIV-1 immunity by adjuvants Document date: 2014_4_10
ID: 1nm1tbig_27
Snippet: There have been multiple human trials with Env protein immunogens combined with different adjuvant formulations (Table 2) [16] [17] [18] 34, 71, [77] [78] [79] [80] . Unfortunately, comparative data are lacking, especially head-to-head comparisons of adjuvants using the same immunogen and dosing schedule. The use of adjuvants in humans demonstrates promise; for example, the AS02A adjuvant formulated with a Env gp120 immunogen was able to elicit s.....
Document: There have been multiple human trials with Env protein immunogens combined with different adjuvant formulations (Table 2) [16] [17] [18] 34, 71, [77] [78] [79] [80] . Unfortunately, comparative data are lacking, especially head-to-head comparisons of adjuvants using the same immunogen and dosing schedule. The use of adjuvants in humans demonstrates promise; for example, the AS02A adjuvant formulated with a Env gp120 immunogen was able to elicit similar titers of antibodies despite a 20-fold difference in the high and low immunogen dose groups, suggesting that the adjuvant might have a dose-sparing effect [71] . Additional studies will be needed to determine the best adjuvant-immunogen combinations for future large-scale trials.
Search related documents:
Co phrase search for related documents- adjuvant formulation and human adjuvant: 1, 2, 3
- adjuvant immunogen and head head: 1
- dose group and head head: 1
- dose group and human trial: 1
Co phrase search for related documents, hyperlinks ordered by date